Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Atreca Inc (BCEL)

OTC Markets
Currency in USD
Disclaimer
0.080
+0.005(+6.67%)
Closed
After Hours
0.077-0.003(-3.75%)
Earnings results expected today
Fair Value
Unlock Value
Day's Range
0.0730.080
52 wk Range
0.0621.264
Prev. Close
0.075
Open
0.073
Day's Range
0.073-0.08
52 wk Range
0.062-1.264
Volume
81,225
Average Volume (3m)
8,009,654
1-Year Change
-93.85%
Shares Outstanding
39,624,075
Fair Value
Unlock
Dividends Payment Streak
Unlock
Analysts
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
2.000
Upside +2,400.000%

People Also Watch

2.990
NVFY
+4.55%
0.68
NXU
-2.29%
3.79
OCEA
-6.77%
1.55
HKIT
-10.92%
0.01
BTTX
8.53%
How do you feel today about BCEL?
Vote to see community's results!
or

Atreca Company Profile

Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company’s ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. Its products in pre-clinical stage include APN-497444, an antibody drug conjugate (ADC) against a novel tumor glycan target; and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. The company was incorporated in 2010 and is based in San Carlos, California.

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.